Navigating Cancer receives ONC-ATCB certification for Patient Engagement Portal

NewsGuard 100/100 Score

Navigating Cancer's Patient Engagement Portal, the industries only oncology specific solution that can integrate with any electronic health record (EHR) system, has received the federal government's "meaningful use" stamp of approval by earning (EHR) modular certification. The designation officially deems Navigating Cancer's solution capable of enabling healthcare providers to qualify for funding under the American Recovery and Reinvestment Act (ARRA). Tested and certified under the Drummond Group's Electronic Health Records Office of the National Coordinator Authorized Testing and Certification Body (ONC-ATCB) program, Navigating Cancer's solution is 2011/2012 compliant in accordance with the criteria adopted by the Secretary of Health and Human Services.  

"We're excited to help our customers achieve meaningful use and qualify for incentive funds under ARRA. By combining Navigating Cancer's Patient Engagement Portal with any certified EHR, oncology practices can quickly achieve meaningful use certification while saving time and money, and improving patient care. We see patient engagement as a way to transform healthcare and are committed to delivering the best patient portal experience to help our customers provide patient centered care," said Gena Cook, Founder and CEO of Navigating Cancer.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer